Get started
AlenCiken

$PRQR Announces Positive Results from Clinical Trial of QR-421a

ProQR Therapeutics N.V. (NASDAQ:PRQR)  
AlenCiken Updated   
NASDAQ:PRQR   ProQR Therapeutics N.V.
Trend Analysis Chart Patterns Fundamental Analysis biotech biotechnology biotechstocks biotechs biotechstock biotehnology
1
0
trendanalysis chartpattern fundamental biotech biotechnology biotechstocks biotechs biotechstock biotehnology
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials.

QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)

QR-421a observed to be well tolerated with no serious adverse events reported

Two pivotal Phase 2/3 trials are expected to start by the end of 2021

finance.yahoo.com/ne...nical-110000726.html
Comment:
Citigroup Reiterated buy $33 → $44
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.